Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Weyl Ben-Arush M, Ben Barak A, Bar-Deroma R, Ash S, Goldstein G, Golan H, Houri H, Waldman D, Nevo N, Bar Shalom R, Berniger A, Nevelsky A, Toren A, Yaniv I, Kuten A.
Weyl Ben-Arush M, et al.
Isr Med Assoc J. 2013 Jan;15(1):31-4.
Isr Med Assoc J. 2013.
PMID: 23484236
Free article.